CRI's new website that seeks to engage, educate, and empower patients and their loved ones to learn more about cancer immunotherapy as a treatment option across numerous tumor types.
Cancer patients, donors, scientists, and other supporters all stand behind the Cancer Research Institute. Read their stories and learn about what motivates each of us to keep fighting against cancer.
Join us on June 25, 2016, for a one-day, multi-distance “Answer to Cancer” cycling event throughout New York's Lower Hudson Valley and sponsored by Bristol-Myers Squibb.
We gratefully accept donations made in memory or in honor of a loved one. Your gift will be acknowledged to whomever you specify.
Hosted by CRI, EATI, CIMT, and AACR, register today for "Translating Science into Survival," on September 25-28, 2016, in New York City.
Curious about the latest developments in cancer immunotherapy research? Listen in as leading scientists discuss immune-based treatments across numerous cancer types in our free "Cancer Immunotherapy and You" webinar series.
When the Cancer Research Institute was founded in 1953, we knew then that immune-based treatments would transform cancer medicine. In more than six decades since, we've made numerous groundbreaking discoveries that have given more patients new hope today.
Welcome to the Cancer Research Institute blog. Here we share the latest updates on the field of cancer immunotherapy from CRI, including scientific breakthroughs, news stories, and program announcements. We invite your comments and encourage you to share these stories with your friends.
You can receive notifications of new posts by subscribing to our blog. Just click the RSS icon in the upper right corner.
April 21, 2016
Arthur N. Brodsky, Ph.D.
cancer research, Coley's toxins, history
breast cancer, cancer research, history, in the news
cancer immunotherapy, cancer research, Coley's toxins, history
cancer, history, in the news
Earlier this month, Team CRI runners ran the 2015 United Airlines Half Marathon in NYC.
community fundraising, marathon, Team CRI
cancer, caregivers, patients
Data from a phase III trial indicate that Keytruda stands ready to become standard-of-care for advanced melanoma.
checkpoint-inhibitor, ipilimumab, melanoma
awards & honors
clinical trials, lung cancer, melanoma
The director of CRI's Scientific Advisory Council talks immunotherapy with the New York Times.
in the news, James Allison, yervoy